Skip to main content

Medigene to Present at ESMO Congress 2024

Written by Customer Service on . Posted in Public Companies.

Planegg/Martinsried, July 23, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today announced the presentation of two posters at the ESMO Congress 2024 being held on September 13-17, 2024, in Barcelona, Spain. The posters will be showcasing recent advancements in the Company’s library of T cell receptors (TCR) targeting Kirsten rat sarcoma viral oncogene homologue (KRAS) as well as its UniTope & TraCR technology, a universal tagging and tracking system for TCR-T cells.

The full abstracts will be published online on the ESMO website (https://www.esmo.org/) on Monday, September 9, 2024, at 00:05 am CEST.

Details of the poster presentations are as follows:

Abstract and title: “Advancing a multi-dimension KRAS mutation-specific T cell receptor (TCR) library with a 3S TCR targeting the G12D mutation to address large global patient populations.”

Authors: Kirsty Crame, Dominik Alterauge, Anne Wiebe Mohr, Julia Bittmann, Doris Brechtefeld, Mario Catarinella, Kathrin Davari, Maja Buerdek, Petra U Prinz, Andrea Coluccio, Dolores J Schendel and Giulia Longinotti
Final presentation number: 1143P
Date/time: Saturday, September 14, 2024, Poster lunch session from noon to 1:00 pm CEST in Hall 6, poster will be on display from 9:00 am to 5:00 pm CEST
Category: Investigational Immunotherapy

Abstract and title: “UniTope & TraCR – Universal tagging and tracking system for TCR-T cells integrated directly in the TCR constant region.”

Authors: Kirsty Crame, Kanuj Mishra, Justyna Ogonek, Dolores Schendel and Barbara Lösch
Final presentation number: 1144P
Date/time: Saturday, September 14, 2024, Poster lunch session from noon to 1 pm CEST in Hall 6, poster will be on display from 9:00 am to 5:00 pm CEST
Category: Investigational Immunotherapy

—  end of press release  —

About Medigene AG

Medigene AG (FSE: MDG1) is an immuno-oncology platform company dedicated to developing differentiated T cell therapies for treatment of solid tumors. Its End-to-End Platform is built on multiple proprietary and exclusive technologies that enable the Company to generate optimal T cell receptors against both cancer testis antigens and neoantigens, armor and enhance these T cell receptor engineered (TCR) -T cells to create best-in-class, differentiated TCR-T therapies, and optimize the drug product composition for safety, efficacy and durability. The End-to-End Platform provides product candidates for both its own therapeutics pipeline and partnering. Medigene’s lead TCR-T program MDG1015 is on track for IND filing in Q3 2024 and CTA filing in Q4 2024. For more information, please visit https://medigene.com/

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.

Medigene AG

Pamela Keck
Phone: +49 89 2000 3333 01
E-mail: investor@medigene.com

In case you no longer wish to receive any information about Medigene, please inform us by e-mail (investor@medigene.com). We will then delete your address from our distribution list.

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.